BioLineRx BLRX shares were trading higher FrIday after the company announced positive results from an interim analysis of the GENESISPphase 3 trial of motixafortide (BL-8040) in stem cell mobilization.
BioLine Rx is a clinical-stage biopharmaceutical development company with a focus on oncology.
Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates: motixafortide (BL-8040), a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors.
In addition, BioLineRx has an off- strategy, legacy therapeutic product, BL-5010, for the treatment of skin lesions.
BioLineRx shares were trading 95.95% higher at $2.90 at last check Friday. The stock has a 52-week high of $3.04 and a 52-week low of $1.06.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.